The medications — a CXCR4 antagonist used for bone marrow transplants and a beta-3 adrenergic agonist for bladder control — could be used to repair bone fractures of the spine, hip and leg post-surgery.
Researchers triggered the bone marrow of healthy rats to release mesenchymal stem cells and aid in the healing of fractures.
The study is led by scientists from Imperial College London in England, and includes researchers from Southfield, Mich.-based Beaumont Health.
More articles on biologics:
Stryker ranks No. 8 in Fortune’s 100 best workplaces
Wuhan neurosurgeon, hospital director dies from coronavirus, death toll rises to 1,800+
Medtronic reports spine revenue up 3%, hurt by low BMP sales: 7 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
